LON:VAL - ValiRx Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 19.74
▼ -0.26 (-1.30%)
1 month | 3 months | 12 months
Get New ValiRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VAL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VAL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ValiRx in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 19.74.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in ValiRx. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
1/12/2018Beaufort SecuritiesReiterated RatingSpeculative Buy
i
12/19/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
11/16/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
i
10/13/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
i
9/27/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
i
9/8/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
i
7/31/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
i
6/16/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
i
5/25/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
i
5/15/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
i
5/8/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
i
3/10/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6
i
3/1/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
1/12/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
12/9/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
12/8/2016Northland SecuritiesReiterated RatingCorporate
i
11/30/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
11/29/2016Northland SecuritiesReiterated RatingCorporate
i
11/3/2016Northland SecuritiesReiterated RatingCorporate
i
10/26/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
10/13/2016Northland SecuritiesReiterated RatingCorporate
i
9/28/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
9/27/2016Northland SecuritiesReiterated RatingCorporate
i
9/14/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
9/13/2016Northland SecuritiesReiterated RatingCorporate
i
8/11/2016Northland SecuritiesReiterated RatingCorporate
i
8/11/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
7/29/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
7/28/2016Northland SecuritiesReiterated RatingCorporate
i
7/14/2016Northland SecuritiesReiterated RatingCorporate
i
7/8/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
7/7/2016Northland SecuritiesReiterated RatingCorporate
i
6/7/2016Northland SecuritiesReiterated RatingCorporate
i
6/7/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
5/19/2016Northland SecuritiesReiterated RatingCorporate
i
5/3/2016Beaufort SecuritiesInitiated CoverageSpeculative Buy
i
4/29/2016Northland SecuritiesReiterated RatingCorporate
i
(Data available from 4/19/2016 forward)
ValiRx logo
ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression Â- implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.
Read More

Today's Range

Now: GBX 19.74
19.25
20.08

50 Day Range

MA: GBX 21.12
19.50
24

52 Week Range

Now: GBX 19.74
3.30
73

Volume

368,544 shs

Average Volume

918,639 shs

Market Capitalization

£12.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ValiRx?

The following equities research analysts have issued stock ratings on ValiRx in the last twelve months:
View the latest analyst ratings for VAL.

What is the current price target for ValiRx?

0 Wall Street analysts have set twelve-month price targets for ValiRx in the last year. has the lowest price target set, forecasting a price of £100,000 for ValiRx in the next year.
View the latest price targets for VAL.

What is the current consensus analyst rating for ValiRx?

ValiRx currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VAL.

What other companies compete with ValiRx?

How do I contact ValiRx's investor relations team?

ValiRx's physical mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company's listed phone number is +44-20-30084416. The official website for ValiRx is www.valirx.com.